Dr. “Lanny” Kirsch received his M.D. from Harvard University Medical School and subsequently completed his Residency at Children’s Hospital Medical Center, Boston, Massachusetts and his Fellowship in Pediatric Hematology/Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland. Dr. Kirsch also completed a three-year postdoctoral fellowship in molecular genetics in the laboratory of Dr. Philip Leder at the National Institute of Child Health and Human Development. Subsequently Dr. Kirsch spent over 20 years at the NCI as a basic researcher, attending physician, and, ultimately, Chief of the Genetics Branch within the Center for Cancer Research. The research interests of Dr. Kirsch have been focusedon cancer specific genetic instability and cancer genetics. In 2005 Dr. Kirsch joined the biotech/pharma company, Amgen, as an Executive Director heading the Oncology Research group at Amgen Washington in Seattle. During the next six years the Amgen Washington group was responsible for bringing a number of different therapeutic targets and modalities to Phase 1 trial evaluation. It also provided basic research support for many projects in late stage clinical development or marketed. Since the beginning of 2012 Dr. Kirsch has been an independent consultant to the biotech/pharma industry with extended assignments focused on the development of antibody therapeutics and molecular diagnostics.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Adaptive Biotechnologies | Senior Vice President of Translational Medicine | Oct 1, 2012 | — | Detail |